| REVIEW |
|
| Year : 2023 | Volume
: 6
| Issue : 1 | Page : 3-8 |
|
|
Current status of clinical application of immunotherapy in the treatment of glioma: A narrative review
Qiuzi Chen1, Peng Ren1, Guohao Huang1, Zuoxin Zhang1, Jean-Philippe Hugnot2, Shengqing Lv1
1 Department of Neurosurgery, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing, China
2 INSERM U 1191 – CNRS UMR 5203, University of Montpellier, Montpellier, France
Correspondence Address:
Prof. Jean-Philippe Hugnot
INSERM U 1191 – CNRS UMR 5203, Université de Montpellier, Montpellier 34094
France
Prof. Shengqing Lv
Department of Neurosurgery, Xinqiao Hospital, Third Military Medical University (Army Medical University), No. 183 Xinqiao Street, Shapingba District, Chongqing 400037
China
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/glioma.glioma_2_23
|
|
|
Glioma is a common type of brain tumor. Current treatment for glioma includes surgical resection, radiotherapy, chemotherapy, and tumor-treating fields. The application of immunotherapy to treat glioma is still far from satisfactory in the clinic. Here, we review the mechanisms of immunotherapy for glioma (including immune checkpoint inhibitor, chimeric antigen receptor-T-cell, tumor vaccine, and oncolytic virus) and the results of completed clinical trials, and will discuss the current status of immunotherapy and possible future directions.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
